GLP-1 Agonist Manufacturing Capacity Expansion
Metabolic Disorders (e.g., Diabetes, Obesity)
Commercial/DevelopmentActive
Key Facts
Indication
Metabolic Disorders (e.g., Diabetes, Obesity)
Phase
Commercial/Development
Status
Active
Company
About Axplora
Axplora is a major global CDMO and API supplier formed in 2021, leveraging the legacy and assets of its acquired entities like Novasep and Farmabios. The company boasts a significant operational footprint with over 2,000 employees across three continents, specializing in the development and manufacturing of complex small molecules, including oncology payloads for ADCs and metabolic disorder treatments. Under CEO Martin Meeson, Axplora is executing a clear growth strategy, marked by substantial capital investments in high-demand therapeutic areas to solidify its position as a technologically advanced partner in the pharmaceutical supply chain.
View full company profile